Literature DB >> 19191683

Clinical benefits versus shortcomings of diltiazem once-daily in the chronotherapy of cardiovascular diseases.

Ugochukwu Ezeugo1, Stephen P Glasser.   

Abstract

BACKGROUND: The introduction of chronotherapy (that is improving a drugs therapeutic efficacy by paralleling the drugs plasma levels to circadian rhythms) has recently become a focus of interest.
OBJECTIVE: This article addresses the efficacy and potential shortcomings of chronotherapy, and focuses on one specific type of chronotherapy: a novel long-acting diltiazem formulation, DTZ-LA.
METHODS: We reviewed the literature to assess the clinical benefits and shortcomings associated with DTZ-LA in the management of hypertension and angina. RESULTS/
CONCLUSIONS: The clinical benefits of DTZ-LA outweigh its disadvantages when surrogate outcomes are evaluated, but it still remains to be determined whether chronotherapy benefits hard clinical outcomes. Nonetheless, chronotherapy has the potential to address the cardiovascular triggers that peak in the early morning hours when the preponderance of cardiovascular events occur, as well as providing better target organ protection compared with non-chronotherapeutic therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19191683     DOI: 10.1517/14656560802694739

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  4 in total

Review 1.  Evening versus morning dosing regimen drug therapy for hypertension.

Authors:  Ping Zhao; Ping Xu; Chaomin Wan; Zhengrong Wang
Journal:  Cochrane Database Syst Rev       Date:  2011-10-05

2.  Chronotherapy for morning blood pressure surge in hypertensive patients: a systematic review and meta-analysis.

Authors:  Ziyan Xie; Jiahao Zhang; Chenyu Wang; Xiaowei Yan
Journal:  BMC Cardiovasc Disord       Date:  2021-06-04       Impact factor: 2.298

3.  Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2).

Authors:  Frank Buttgereit; Daksha Mehta; John Kirwan; Jacek Szechinski; Maarten Boers; Rieke E Alten; Jerzy Supronik; Istvan Szombati; Ulrike Romer; Stephan Witte; Kenneth G Saag
Journal:  Ann Rheum Dis       Date:  2012-05-05       Impact factor: 19.103

Review 4.  Chronopharmacology of anti-convulsive therapy.

Authors:  Sriram Ramgopal; Sigride Thome-Souza; Tobias Loddenkemper
Journal:  Curr Neurol Neurosci Rep       Date:  2013-04       Impact factor: 5.081

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.